A Spatio-Temporal Model of Macrophage-Mediated Drug Resistance in Glioma Immunotherapy
Authors:
- 1 April 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 17 (4) , 814-824
Abstract
The emergence of drug resistance is often an inevitable obstacle that limits the long-term effectiveness of clinical cancer chemotherapeutics. Although various forms of cancer cell-intrinsic mechanisms of drug resistance have been experimentally revealed, the role and the underlying mechanism of tumor microenvironment in driving the development of acquired drug resistance remain elusive, which significantly impedes effective clinical cancer treatment. Recent experimental studies have revealed a macrophage-mediated drug resistance mechanism in which the tumor microenvironment undergoes adaptation in response to macrophage-targeted colony-stimulating factor-1 receptor (CSF1R) inhibition therapy in gliomas. In this study, we developed a spatio-temporal model to quantitatively describe the interplay between glioma cells and CSF1R inhibitor–targeted macrophages through CSF1 and IGF1 pathways. Our model was used to investigate the evolutionary kinetics of the tumor regrowth and the associated dynamic adaptation of the tumor microenvironment in response to the CSF1R inhibitor treatment. The simulation result obtained using this model was in agreement with the experimental data. The sensitivity analysis revealed the key parameters involved in the model, and their potential impacts on the model behavior were examined. Moreover, we demonstrated that the drug resistance is dose-dependent. In addition, we quantitatively evaluated the effects of combined CSFR inhibition and IGF1 receptor (IGF1R) inhibition with the goal of designing more effective therapies for gliomas. Our study provides quantitative and mechanistic insights into the microenvironmental adaptation mechanisms that operate during macrophage-targeted immunotherapy and has implications for drug dose optimization and the design of more effective combination therapies. Mol Cancer Ther; 17(4); 814–24. ©2018 AACR.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (61503419)
- Guangdong Nature Science Foundation (2014A030310355, 2016A030313234)
- Guangdong Provincial Key Laboratory of Orthopedics and Traumatology (2016B030301002)
- National Key Research Project of China (91530320, 2014CB964703)
This publication has 46 references indexed in Scilit:
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- Cellular Constituents of Immune Escape within the Tumor MicroenvironmentCancer Research, 2012
- In silico Experimentation of Glioma Microenvironment Development and Anti-tumor TherapyPLOS Computational Biology, 2012
- Clonal evolution in cancerNature, 2012
- Accurate state estimation from uncertain data and models: an application of data assimilation to mathematical models of human brain tumorsBiology Direct, 2011
- Granulocyte Macrophage Colony-Stimulating Factor Inhibits Breast Cancer Growth and Metastasis by Invoking an Anti-Angiogenic Program in Tumor-Educated MacrophagesCancer Research, 2009
- A methodology for performing global uncertainty and sensitivity analysis in systems biologyJournal of Theoretical Biology, 2008
- An evolutionary hybrid cellular automaton model of solid tumour growthJournal of Theoretical Biology, 2007
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Colony stimulating factor-1 expression in human gliomaMolecular and Chemical Neuropathology, 1994